Recent News

• 04.22.2025 - Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody
• 04.22.2025 - Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody
• 03.27.2025 - H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
• 03.11.2025 - Leerink Partners Global Healthcare Conference
• 03.04.2025 - Aclaris Therapeutics to Participate in Two March Healthcare Conferences
• 02.27.2025 - Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
• 02.12.2025 - New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Recent Filings

• 04.14.2025 - PRE 14A Other preliminary proxy statements
• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.07.2025 - EFFECT Notice of Effectiveness
• 03.05.2025 - CORRESP Correspondence
• 03.04.2025 - UPLOAD SEC-generated letter
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.27.2025 - EX-99.1 EX-99.1
• 02.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]